New Lonza site can now make Covid-19 vaccine ingredient
Construction of an antibody production line at the new Lonza plant
Keystone / Olivier Maire
Swissmedic, the Swiss Agency for Therapeutic Products, has approved pharmaceutical company Lonza’s new site for making Moderna’s Covid-19 active substance.
This content was published on
1 minute
swissinfo.ch/sm
Español
es
Nuevo sitio de Lonza ya puede fabricar ingrediente de vacuna COVID-19
It issued the licence following a successful inspection of the production plant in Visp in southern Switzerland. At this newly approved site Lonza can manufacture, on behalf of Moderna, active substances for Covid-19 vaccines.
Swissmedic had already approved the first Swiss plant for the production of the substance in January 2021. At this newly approved site, called “Ibex® Solutions”, one production line is fully operational, and two more lines should be available soon.
Companies that manufacture or distribute medicinal or transplant products in Switzerland require an establishment licence proving that a company has the resources and processes needed to ensure and constantly monitor the quality of their products.
Lonza has a ten-year contract to supply ingredients to Moderna, including for up to one billion doses annually of Covid-19 vaccine.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
Swiss political class divided over reform of EU asylum pact
This content was published on
As a result of the EU's Migration and Asylum Pact, Switzerland must adapt five laws linked to the Schengen/Dublin agreements.
AI can reduce the number of animals needed for research
This content was published on
Swiss researchers have developed a new, AI-supported method that analyses the behaviour of mice in the laboratory more efficiently.
Geneva Conventions conference on Middle East scheduled for March 2025
This content was published on
The conference on the Middle East of the 196 States party to the Geneva Conventions, organised by Switzerland, will take place in Geneva in March.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.